

PUBLICATIONS AND PATENTS

Publications

Total number of publications: 219

Number of publications jointly authored between Divisions and Groups: 32

Cancer and Haematology Division

Primary

1. Adams TE, Hansen JA, Starr R, Nicola NA, Hilton DJ and Billestrup N. Growth hormone preferentially induces the rapid, transient expression of SOCS-3, a novel inhibitor of cytokine receptor signaling. *J Biol Chem* 273: 1285–1287, 1998
2. Augstein P, Elefanty AG, Allison J and Harrison LC. Apoptosis and β -cell destruction in pancreatic islets of NOD mice with spontaneous and cyclophosphamide-accelerated diabetes. *Diabetologia* (in press)
3. Augstein P, Stephens LA, Allison J, Elefanty AG, Ekberg M, Kay TWH and Harrison LC. β -cell apoptosis in an accelerated model of autoimmune diabetes. *Mol Med* (in press)
4. Bassler RL, To LB, Begley CG, Maher D, Juttner C, Cebon J, Mansfield R, Olver I, Duggan G, Szer J, Collins J, Schwartz B, Marty J, Menchaca D, Sheridan WP, Fox RM and Green MD. Rapid hematopoietic recovery after multicycle high-dose chemotherapy: enhancement of filgrastim-induced progenitor-cell mobilization by recombinant human stem-cell factor. *J Clin Oncol* 16: 1899–1908, 1998
5. Biben C, Stanley E, Fabri L, Kotecha S, Rhinn M, Drinkwater C, Lah M, Wang CC, Nash A, Hilton DJ, Ang SL, Mohun T and Harvey RP. Murine cerberus homologue mCer-1: a candidate anterior patterning molecule. *Dev Biol* 194: 135–151, 1998
6. Cambier N, Chopra R, Strasser A, Metcalf D and Elefanty AG. BCR-ABL activates pathways mediating cytokine independence and protection against apoptosis in murine hematopoietic cells in a dose-dependent manner. *Oncogene* 16: 335–348, 1998
7. Curtis DJ, Hilton DJ, Roberts B, Murray L, Nicola NA and Begley CG. Recombinant soluble interleukin-11 (IL-11) receptor alpha-chain can act as an IL-11 antagonist. *Blood* 90: 4403–4412, 1997
8. Curtis DJ, Robb L, Strasser A and Begley CG. The *CD2-scl* transgene alters the phenotype and frequency of T-lymphomas in N-ras transgenic or p53 deficient mice. *Oncogene* 15: 2975–2983, 1997
9. Douglas AM, Grant SL, Goss GA, Clouston DR, Sutherland RL and Begley CG. Oncostatin M induces the differentiation of breast cancer cells. *Int J Cancer* 75: 64–73, 1998
10. Elwood NJ, Zogos H, Pereira DS, Dick JE and Begley CG. Enhanced megakaryocyte and erythroid development from normal human CD34⁺ cells: consequence of enforced expression of SCL. *Blood* 91: 3756–3765, 1998
11. Gainsford T, Roberts AW, Kimura S, Metcalf D, Dranoff G, Mulligan RC, Begley CG, Robb L and Alexander WS. Cytokine production and function in *c-mpl*-deficient mice: no physiologic role for interleukin-3 in residual megakaryocyte and platelet production. *Blood* 91: 2745–2752, 1998
12. Göttgens B, McLaughlin F, Bockamp EO, Fordham JL, Begley CG, Kosmopoulos K, Elefanty AG and Green AR. Transcription of the SCL gene in erythroid and CD34 positive primitive myeloid cells is controlled by a complex network of lineage-restricted chromatin-dependent and chromatin-independent regulatory elements. *Oncogene* 15: 2419–2428, 1997
13. Hammacher A, Richardson RT, Layton J, Smith DK, Angus L, Hilton DJ, Nicola NA, Wijdenes J and Simpson RJ. The immunoglobulin-like module of gp130 is required for signaling by interleukin-6 but not leukemia inhibitory factor. *J Biol Chem* (in press)
14. Hilton DJ, Richardson RT, Alexander WS, Viney EM, Willson TA, Sprigg NS, Starr R, Nicholson SE, Metcalf D and Nicola NA. Twenty proteins containing a C-terminal SOCS box form five structural classes. *Proc Natl Acad Sci USA* 95: 114–119, 1998
15. Hinds MG, Maurer T, Zhang JG, Nicola NA and Norton RS. Solution structure of leukemia inhibitory factor. *J Biol Chem* 273: 13738–13745, 1998
16. Kimura S, Roberts AW, Metcalf D and Alexander WS. Hematopoietic stem cell deficiencies in mice lacking *c-Mpl*, the receptor for thrombopoietin. *Proc Natl Acad Sci USA* 95: 1195–1200, 1998
17. Metcalf D. Murine hematopoietic stem cells committed to macrophage/dendritic cell formation: stimulation by Flk2-ligand with enhancement by regulators using the gp130 receptor chain. *Proc Natl Acad Sci USA* 94: 11552–11556, 1997
18. Metcalf D. Lineage commitment in the progeny of murine hematopoietic pre-progenitor cells: influence of thrombopoietin and interleukin-5. *Proc Natl Acad Sci USA* 95: 6408–6412, 1998
19. Metcalf D, Mifsud S, Di Rago L, Robb L, Nicola NA and Alexander WS. The biological consequences of excess GM-CSF levels in transgenic mice also lacking high-affinity receptors for GM-CSF. *Leukemia* 12: 353–362, 1998
20. Novak U, Nicholson S, Bourette RP, Rohrschneider LR, Alexander WS and Paradiso L. CSF-1 and interferon- γ act synergistically to promote differentiation of FDC-P1 cells into macrophages. *Growth Factors* 15: 159–171, 1998
21. Ogilvy S, Elefanty AG, Visvader J, Bath ML, Harris AW and Adams JM. Transcriptional regulation of *vav*, a gene expressed throughout the hematopoietic compartment. *Blood* 91: 419–430, 1998
22. Orchansky PL, Ayres SD, Hilton DJ and Schrader JW. An interleukin (IL)-13 receptor lacking the cytoplasmic domain fails to transduce IL-13-induced signals and inhibits responses to IL-4. *J Biol Chem* 272: 22940–22947, 1997
23. Robb L, Li R, Hartley L, Nandurkar HH, Köntgen F and Begley CG. Infertility in female mice lacking the receptor for interleukin 11 is due to a defective uterine response to implantation. *Nat Med* 4: 303–308, 1998
24. Robb L, Mifsud L, Hartley L, Biben C and Harvey RP. Epicardin: a basic helix-loop-helix transcription factor gene expressed in epicardium, branchial arch myoblasts and mesenchyme of developing lung, gut, kidney and gonads. *Dev Dyn* (in press)
25. Roberts AW, Zaiss M, Boyd AW and Nicola NA. G-CSF-mobilized peripheral blood progenitor cells: *in vitro* growth pattern and hematopoietic growth factor receptor profile. *Exp Hematol* 25: 298–305, 1997

26. Stanley E, Gilbert DG, Jenkins NA, Copeland NG and Harvey RP. Murine *cerberus* homologue *Cer1* maps to chromosome 4. *Genomics* 49: 337–338, 1998
27. Woolley I, Curtis D, Szer J, Fairley C, Vujovic O, Ugoni A and Spelman D. High dose cytosine arabinoside is a major risk factor for the development of hepatosplenic candidiasis in patients with leukemia. *Leuk Lymphoma* 27: 469–474, 1997
28. Zhang JG, Zhang Y, Owczarek CM, Ward LD, Moritz RL, Simpson RJ, Yasukawa K and Nicola NA. Identification and characterization of two distinct truncated forms of gp130 and a soluble form of leukemia inhibitory factor receptor alpha-chain in normal human urine and plasma. *J Biol Chem* 273: 10798–10805, 1998
29. Zhang MY, Clawson GA, Olivieri NF, Bell LL, Begley CG and Miller BA. Expression of SCL is normal in transfusion-dependent Diamond-Blackfan anemia but other bHLH proteins are deficient. *Blood* 90: 2068–2074, 1997

Reviews and Books

30. Alexander WS and Begley CG. Thrombopoietin *in vitro* and *in vivo*. *Cytokines Cell Mol Ther* 4: 25–34, 1998
31. Harris AW, Strasser A, Elefanty AG, Bath ML and Cory S. Deregulation of cell survival in lymphomagenesis. *Leukemia* 11 Suppl 3: 383–384, 1997
32. Metcalf D. Regulatory mechanisms controlling hematopoiesis: principles and problems. *Stem Cells* 16: 3–11, 1998
33. Metcalf D. Cell-cell signalling in the regulation of blood cell formation and function. *Immunol Cell Biol* (in press)
34. Metcalf D. Mechanisms of human hematopoiesis. In: Thomas ED, ed. *Hematopoietic cell transplantation*. (in press)
35. Metcalf D. The molecular control of hematopoiesis: progress and problems with gene manipulation. *Stem Cells* (in press)
36. Metcalf D. The molecular regulation of granulocytes and macrophages. In: *Dermatology at the millennium* (in press)
37. Metcalf D. Stem cells pre-progenitor cells and lineage committed cells: Are our dogmas correct? *Ann N Y Acad Sci* (in press)
38. Metcalf D. The Charlotte Friend Memorial Lecture. The role of hematopoietic growth factors in the development and suppression of myeloid leukemias. *Leukemia* 11: 1599–1604, 1997
39. Metcalf D. Lineage commitment and maturation in hematopoietic cells: the case for extrinsic regulation. *Blood* 92: 345–352, 1998
40. Metcalf D. Pre-progenitor cells: a proposed new category of hematopoietic precursor cells. *Leukemia* 12: 1–3, 1998
41. Metcalf D, Nicola NA and Robb L. Differentiation commitment in normal hemopoiesis and leukemic transformation. *J Cell Physiol* 173: 131–134, 1997
42. Nicholson SE and Hilton DJ. The SOCS proteins: a new family of negative regulators of signal transduction. *J Leukoc Biol* 63: 665–668, 1998
43. Robb L and Elefanty AG. The haemangioblast – an elusive cell captured in culture. *Bioessays* (in press)
44. Robb L, Elefanty AG and Begley CG. Transcriptional control of hematopoiesis. In: Norden R and Schindhelm K, eds. *Ex vivo cell therapy*. Texas: Landes (in press)
45. Starr R and Hilton DJ. Molecules in focus-SOCS: suppressors of cytokine signalling. *Int J Biochem Cell Biol* (in press)
46. Starr R and Hilton DJ. Negative regulation of cytokine signal transduction pathways. *Bioessays* (in press)
47. Starr R and Hilton DJ. SOCS proteins: a new family of negative regulators of cytokine signal transduction. In: Haussinger D, ed. *Signalling in the liver: Falk Symposium*. Lancaster: Kluwer Academic: 82–87 (in press)
48. Starr R and Nicola NA. Cell signaling by hemopoietic growth factor receptors. In: Norden R and Schindhelm K eds. *Ex vivo cell therapy*. Texas: Landes, (in press)

Molecular Genetics of Cancer Division

Primary

49. Cambier N, Chopra R, Strasser A, Metcalf D and Elefanty AG. BCR-ABL activates pathways mediating cytokine independence and protection against apoptosis in murine hematopoietic cells in a dose-dependent manner. *Oncogene* 16: 335–348, 1998
50. Curtis DJ, Robb L, Strasser A and Begley CG. The *CD2-scl* transgene alters the phenotype and frequency of T-lymphomas in N-ras transgenic or p53 deficient mice. *Oncogene* 15: 2975–2983, 1997
51. Grumont RJ, Rourke IJ, O'Reilly LA, Strasser A, Miyake K, Sha W and Gerondakis S. B lymphocytes differentially use the Rel and nuclear factor κ B1 (NF- κ B1) transcription factors to regulate cell cycle progression and apoptosis in quiescent and mitogen-activated cells. *J Exp Med* 187: 663–674, 1998
52. Gugasyan R, Coward A, O'Connor L, Shortman K and Scollay R. Emigration of mature T cells from the thymus is inhibited by the imidazole-based compound 2-acetyl-4-tetrahydroxybutylimidazole. *Immunology* 93: 398–404, 1998
53. Harris AW, Basten A, GebSKI V, Noonan D, Finnie J, Bath ML, Bangay MJ and Repacholi MH. A test of lymphoma induction by long-term exposure of *Em-Pim1* transgenic mice to 50 Hz magnetic fields. *Radiat Res* 149: 300–307, 1998
54. Hawkins CJ, Ekert PG, Uren AG, Holmgren SP and Vaux DL. Anti-apoptotic potential of insect cellular and viral IAPs in mammalian cells. *Cell Death Differ* (in press)
55. Huang DCS, Adams JM and Cory S. The conserved N-terminal BH4 domain of Bcl-2 homologues is essential for inhibition of apoptosis and interaction with CED-4. *EMBO J* 17: 1029–1039, 1998
56. Innes KM, Szilvassy SJ, Davidson HE, Gibson L, Adams JM and Cory S. Retroviral transduction of enriched hematopoietic stem cells allows life-long Bcl-2 expression in multiple lineages but does not perturb hematopoiesis. *Exp Hematol* (in press)
57. Janani R, Harris AW, Strasser A, Dhanoa S, Plyam R and Osmond DG. Effect of *bcl-2* transgene on production and localization of precursor B cells in mouse bone marrow. *Exp Hematol* (in press)
58. Lang J, Arnold B, Hammerling G, Harris AW, Korsmeyer S, Russell D, Strasser A and Nemazee D. Enforced Bcl-2 expression inhibits antigen-mediated clonal elimination of peripheral B cells in an antigen dose-dependent manner and promotes receptor editing in autoreactive immature B cells. *J Exp Med* 186: 1513–1522, 1997
59. Maraskovsky E, Peschon JJ, McKenna H, Teepe M and Strasser A. Overexpression of Bcl-2 does not rescue impaired B lymphopoiesis in interleukin-7 receptor-deficient mice but can enhance survival of mature B cells. *Int Immunol* (in press)
60. Morahan G, Huang DCS, Yu WP, Cui L, DeAizpurua H and Pallen CJ. Localization of the genes encoding the type I diabetes autoantigens, protein-tyrosine phosphatases IA2 and IAR. *Mamm Genome* 9: 593–594, 1998
61. Newton K, Harris AW, Bath ML, Smith KGC and Strasser A. A dominant interfering mutant of FADD/MORT1 enhances deletion of autoreactive thymocytes and inhibits proliferation of mature T lymphocytes. *EMBO J* 17: 706–718, 1998
62. Ogilvy S, Elefanty AG, Visvader J, Bath ML, Harris AW and Adams JM. Transcriptional regulation of *vav*, a gene expressed throughout the hematopoietic compartment. *Blood* 91: 419–430, 1998
63. O'Connor L, Strasser A, O'Reilly LA, Hausmann G, Adams JA, Cory S and Huang DCS. Bim: a novel member of the Bcl-2 family that promotes apoptosis. *EMBO J* 17: 384–395, 1998
64. Petschner F, Zimmerman C, Strasser A, Grillot D, Nunez G and Pircher H. Constitutive expression of Bcl-x_L or Bcl-2 prevents peptide antigen-induced T cell deletion but does not influence

- T cell homeostasis after a viral infection. *Eur J Immunol* 28: 560–569, 1998
65. Sutton VR, Vaux DL and Trapani JA. Bcl-2 prevents apoptosis induced by perforin and granzyme B, but not that mediated by whole cytotoxic lymphocytes. *J Immunol* 158: 5783–5790, 1997
66. Vadiveloo PK, Vairo G, Royston AK, Novak U and Hamilton JA. Proliferation independent induction of macrophage cyclin D2, and repression of cyclin D1 by lipopolysaccharide. *J Biol Chem* (in press)
67. Vaux DL, Wilhelm S and Häcker G. Requirements for proteolysis during apoptosis. *Mol Cell Biol* 17: 6502–6507, 1997
68. Watanabe G, Albanese C, Lee RJ, Reutens A, Vairo G, Henglein B and Pestell RG. Inhibition of cyclin D kinase activity is associated with E2F-mediated inhibition of cyclin D1 promoter activity through E2F and Sp1. *Mol Cell Biol* 18: 3212–3222, 1998
- Reviews and Books**
69. Adams JM and Cory S. The Bcl-2 protein family: arbiters of cell survival. *Science* (in press)
70. Cory S and Adams JM. Matters of life and death: Programmed Cell Death at Cold Spring Harbor. *Biochim Biophys Acta* 1377: R25–R44, 1998
71. Ekert PG and Vaux DL. Apoptosis and the immune system. *Br Med Bull* 53: 591–603, 1997
72. Ekert PG and Vaux DL. Apoptosis, haemopoiesis and leukaemogenesis. *Baillieres Clin Haematol* 10: 561–576, 1997
73. Häcker G and Vaux DL. A chronology of cell death. *Apoptosis* 2: 247–256, 1998
74. Harris AW, Strasser A, Elefanty AG, Bath ML and Cory S. Deregulation of cell survival in lymphomagenesis. *Leukemia* 11 Suppl 3: 383–384, 1997
75. Newton K and Strasser A. The Bcl-2 family and cell death regulation. *Curr Opin Genet Dev* 8: 68–75, 1998
76. O'Connor L and Strasser A. The Bcl-2 protein family. In: *Results and problems in cell differentiation*. Heidelberg: Springer-Verlag (in press)
77. Strasser A, Newton K, Huang DCS, O'Connor L, O'Reilly LA, Puthalakath H, Bath ML, Cullen L, Stanley ML, Tarlinton DM, Allison J, Smith KGC, Vaux DL, Adams JM, Cory S and Harris AW. The molecular control of lymphocyte apoptosis. In: *Proceedings of the 5th Euro-conference on apoptosis*. Bingen, Germany: European School of Haematology; 7pp, 1997.
78. Strasser A and O'Connor L. Fas ligand-caught between Scylla and Charybdis. *Nat Med* 4: 21–22, 1998
79. Uren AG, Coulson EJ and Vaux DL. Conservation of baculovirus inhibitor of apoptosis repeat proteins (BIRPs) in viruses, nematodes, vertebrates and yeasts. *Trends Biochem Sci* 23: 159–162, 1998
80. Uren AG and Vaux DL. Viral inhibitors of apoptosis. *Vitam Horm* 53: 175–193, 1997
81. Vairo G. Australian Society for Biochemistry and Molecular Biology (ASBMB) 41st annual meeting (part IV). *ID Weekly Highlights* 45: 34–38, 1997
82. Vaux DL. CED-4-the third horseman of apoptosis. *Cell* 90: 389–390, 1997
83. Vaux DL. Immunopathology of apoptosis-introduction and overview. *Springer Semin Immunopathol* 19: 271–278, 1998
84. Vaux DL, Hawkins CJ, Uren AG and Ekert PG. Motor neurone disease and the life of motor neurones. *Med J Aust* 166: 109–110, 1997
86. Antica M, Wu L and Scollay R. Stem cell antigen 2 expression in adult and developing mice. *Immunol Lett* 55: 47–51, 1997
87. Barnden MJ, Allison J, Heath WR and Carbone FR. Defective TCR expression in transgenic mice constructed using cDNA-based alpha-and beta-chain genes under the control of heterologous regulatory elements. *Immunol Cell Biol* 76: 34–40, 1998
88. Bennett SRM, Carbone FR, Karamalis F, Flavell RA, Miller JFAP and Heath WR. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. *Nature* 393: 478–480, 1998
89. Greenman J, Jones E, Wright MD and Barclay AN. The use of intracellular single-chain antibody fragments to inhibit specifically the expression of cell surface molecules. *J Immunol Methods* 194: 169–180, 1996
90. Grumont RJ, Rourke IJ, O'Reilly LA, Strasser A, Miyake K, Sha W and Gerondakis S. B lymphocytes differentially use the Rel and nuclear factor κ B1 (NF- κ B1) transcription factors to regulate cell cycle progression and apoptosis in quiescent and mitogen-activated cells. *J Exp Med* 187: 663–674, 1998
91. Gugasyan R, Coward A, O'Connor L, Shortman K and Scollay R. Emigration of mature T cells from the thymus is inhibited by the imidazole-based compound 2-acetyl-4-tetrahydroxybutylimidazole. *Immunology* 93: 398–404, 1998
92. Humbert PO and Corcoran LM. *oct-2* gene disruption eliminates the peritoneal B-1 lymphocyte and attenuates B-2 cell maturation and function. *J Immunol* 159: 5273–5284, 1997
93. Kelley CM, Ikeda T, Koipally J, Avitahl N, Wu L, Georgopoulos K and Morgan BA. Helios, a novel dimerization partner of Ikaros expressed in the earliest hematopoietic progenitors. *Curr Biol* 8: 508–515, 1998
94. Koniaras C, Heath WR and Lew AM. T cell unresponsiveness *in vitro* can be due to activation *in vivo*. *Int Immunol* 10: 365–369, 1998
95. Kronin V, Vremec D and Shortman K. Does the IL-2R α -chain induced on dendritic cells have a biological function? *Int Immunol* 10: 237–240, 1998
96. Kurek JB, Bower JJ, Romanella M, Köntgen F, Murphy M and Austin L. The role of leukemia inhibitory factor in skeletal muscle regeneration. *Muscle Nerve* 20: 815–822, 1997
97. Kurts K, Carbone FR, Barnden M, Blanas E, Allison JA, Heath WR and Miller JFAP. CD4⁺ T cell help impairs CD8⁺ T cell deletion induced by cross-presentation of self-antigens and favors autoimmunity. *J Exp Med* 186: 2057–2062, 1997
98. Kurts K, Heath WR, Kosaka H, Miller JFAP and Carbone FR. The peripheral deletion of autoreactive CD8⁺ T cells induced by cross-presentation of self-antigens involves signalling through CD95 (Fas,Apo-1). *J Exp Med* 188: 415–420, 1998
99. Kurts K, Miller JFAP, Subramanian RM, Carbone FR and Heath WR. Major histocompatibility complex class I-restricted cross-presentation is biased towards high dose antigens and those released during cellular destruction. *J Exp Med* 188: 409–414, 1998
100. Li S, Kurts C, Köntgen F, Holdsworth SR and Tipping PC. MHC class II expression by intrinsic renal cells is required for crescentic glomerulonephritis. *J Exp Med* 188: 597–602, 1998
101. Ridderstad A and Tarlinton DM. Kinetics of establishing the memory B cell population as revealed by CD38 expression. *J Immunol* 160: 4688–4695, 1998
102. Smith KGC, Tarlinton DM, Doody GM, Hibbs ML and Fearon DT. Inhibition of the B cell by CD22: a requirement for Lyn. *J Exp Med* 187: 807–811, 1998
103. Winkel KD, Kronin V, Krummel MF and Shortman K. The nature of the signals regulating CD8 T cell proliferative responses to CD8 α ⁺ or CD8 α ⁻ dendritic cells. *Europ J Immunol* 27: 3350–3359, 1997
104. Wu L, Nichogioannopoulou A, Shortman K and Georgopoulos K. Cell autonomous defects in dendritic cell populations of Ikaros mutant mice point to a developmental relationship with the lymphoid lineage. *Immunity* 7: 483–492, 1997

Immunology Division

Primary

85. Allison JA, Stephens LA, Kay TW, Kurts C, Heath WR, Miller JFAP and Krummel MF. The threshold for autoimmune T cell killing is influenced by B7-1. *Eur J Immunol* 28: 949–960, 1998

Reviews and Books

105. Blanas E and Heath WR. Induction of autoimmune diseases by oral administration of antigen. *Int Rev Immunol* (in press)
106. Carbone FR, C Kurts, Bennett S, Miller JFAP and Heath WR. Cross-presentation: a general mechanism for CTL immunity and tolerance. *Immunol Today* 19: 367–373, 1998
107. Galy A, Georgopoulos K and Wu L. Hematopoietic cell fate and the development of dendritic cells. In: Lotze MT and Thomson AW eds. *Dendritic cells: biology and clinical applications*. San Diego: Academic Press (in press)
108. Gerondakis S, Grumont R, Rourke IJ and Grossmann M. The regulation and roles of Rel/NF- κ B transcription factors during lymphocyte activation. *Curr Opin Immunol* 10: 353–359, 1998
109. Heath WR, Kurts C, Miller JFAP and Carbone FR. Cross-tolerance: a pathway for inducing tolerance to peripheral tissue antigens. *J Exp Med* 187: 1549–1553, 1998
110. Miller JFAP. Discovering the origins of immunological competence. *Ann Rev Immunol* (in press)
111. Miller JFAP, Kurts C, Allison JA, Kosaka H, Carbone FR and Heath WR. Induction of peripheral CD8⁺ T-cell tolerance by cross-presentation of self antigens. *Immunol Rev* (in press)
112. Shortman K and Caux C. Dendritic cell development: multiple pathways to Nature's adjuvants. *Stem Cells* 15: 409–419, 1997
113. Shortman K, Vremec D, Corcoran LM, Georgopoulos K, Lucas K and Wu L. The linkage between T cell and dendritic cell development in the mouse thymus. *Immunol Rev* (in press)
114. Strasser A, Newton K, Huang DCS, O'Connor L, O'Reilly LA, Puthalakath H, Bath ML, Cullen L, Stanley ML, Tarlinton DM, Allison J, Smith KGC, Vaux DL, Adams JM, Cory S and Harris AW. The molecular control of lymphocyte apoptosis. In: *Proceedings of the 5th Euro-conference on apoptosis*. Bingen, Germany: European School of Haematology; 7pp, 1997.
115. Tarlinton DM. Germinal centers: form and function. *Curr Opin Immunol* 10: 245–251, 1998
116. Tarlinton DM, Light A, Nossal GJV and Smith KGC. Affinity maturation of the primary response by V gene diversification. *Curr Top Microbiol Immunol* 229: 71–83, 1998
117. Wu L, Livak F and Petrie HT. TCR-independent development of pluripotent T cell precursors. In: Monroe JG and Rothenberg E, eds. *Molecular biology of B and T lymphocyte development*. New Jersey, Humana Press (in press)
118. Wu L and Shortman K. Isolation and characterisation of murine early intrathymic precursor populations. In: *Protocols in T cell development and activation* (in press)
123. Cowman AF, Deady LW, Deharo E, Desneves J and Tilley L. Synthesis and activity of some antimalarial bisquinolinemethanols. *Aust J Chem* 50: 1091–1096, 1997
124. Crabb BS, Triglia T, Waterkeyn JG and Cowman AF. Stable transgene expression in *Plasmodium falciparum*. *Mol Biochem Parasitol* 90: 131–144, 1997
125. Fu Y, Shearing LN, Haymes S, Crewther PE, Tilley L, Anders RF and Foley M. Isolation from phage display libraries of single chain variable fragment antibodies that recognize conformational epitopes in the malaria vaccine candidate apical membrane antigen-1. *J Biol Chem* 272: 25678–25684, 1997
126. Humberstone AJ, Cowman AF, Horton J and Charman WN. Effect of altered serum lipid concentrations on the IC50 of halofantrine against *Plasmodium falciparum*. *J Pharm Sci* 87: 256–258, 1998
127. Kemp M, Handman E, Kemp K, Ismail A, Mustafa MD, Kordofani AY, Bendtzen K, Kharazmi A and Theander TG. The Leishmania promastigote surface antigen-2 (PSA-2) is specifically recognised by Th1 cells in humans with naturally acquired immunity to *L. major*. *FEMS Immunol Med Microbiol* 20: 209–218, 1998
128. Marshall VM, Silva A, Foley M, Cranmer S, Wang L, McColl DJ, Kemp DJ and Coppel RL. A second merozoite surface protein (MSP-4) of *Plasmodium falciparum* that contains an epidermal growth factor-like domain. *Infect Immun* 65: 4460–4467, 1997
129. Menting JGT, Tilley L, Deady LW, Ng K, Simpson RJ, Cowman AF and Foley M. The antimalarial drug, chloroquine, interacts with lactate dehydrogenase from *Plasmodium falciparum*. *Mol Biochem Parasitol* 88: 215–224, 1997
130. Pye D, Vandenberg KL, Dyer SL, Irving DO, Goss NH, Woodrow GC, Saul A, Alving CR, Richards RL, Ballou WR, Wu MJ, Skoff K, Anders RF. Selection of an adjuvant for vaccination with the malaria antigen, MSA-2. *Vaccine* 15: 1017–1023, 1997
131. Sjölander A, Baldwin TM, Curtis JM, Lovgren Bengtsson K and Handman E. Vaccination with recombinant parasite surface antigen 2 from *Leishmania major* induces a Th1 type of immune response but does not protect against infection. *Vaccine* (in press)
132. Sjölander A, Baldwin TM, Curtis JM and Handman E. Induction of a Th1 immune response and simultaneous lack of activation of a Th2 response are required for generation of immunity to leishmaniasis. *J Immunol* 160: 3949–3957, 1998
133. Thompson JK and Cowman AF. A YAC contig and high resolution restriction map of chromosome 3 from *Plasmodium falciparum*. *Mol Biochem Parasitol* 90: 537–542, 1997
134. Triglia T, Wang P, Sims PFG, Hyde JE and Cowman AF. Allelic exchange at the endogenous genomic locus in *Plasmodium falciparum* proves the role of dihydropteroate synthase in sulfadoxine-resistant malaria. *EMBO J* 17: 3807–3815, 1998

Infection and Immunity Division

Primary

119. Al-Yaman F, Genton B, Taraika J, Anders R and Alpers MP. Association between cellular response (IL-4) to RESA/Pf 155 and protection from clinical malaria among Papua New Guinean children living in a malaria endemic area. *Parasite Immunol* 19: 249–254, 1997
120. Amante FH, Crewther PE, Anders RF and Good MF. A cryptic T cell epitope on the apical membrane antigen 1 of *Plasmodium chabaudi adami* can prime for an anamnestic antibody response: implications for malaria vaccine design. *J Immunol* 159: 5535–5544, 1997
121. Beeson JG, Chai W, Rogerson SJ, Lawson AM and Brown GV. Inhibition of binding of malaria-infected erythrocytes by a tetradecasaccharide fraction from chondroitin sulfate A. *Infect and Immun* 66: 3397–3402, 1998
122. Bennett BJ, Mohandas N and Coppel RL. Defining the minimal domain of the *Plasmodium falciparum* protein MESA involved in the interaction with the red cell membrane skeletal protein 4.1. *J Biol Chem* 272: 15299–15306, 1997

Reviews and Books

135. Anders RF, Crewther PE and Hodder AN. Apical membrane antigen 1: a leading malaria vaccine candidate. *Australas Biotechnol* 8: 91–95, 1998
136. Brown GV and Mitchell GF. Immunology of parasitism. In: Dulbecco R, ed. *Encyclopedia of human biology*. San Diego: Academic Press; 761–766, 1997
137. Coppel RL, Brown GV and Nussenzweig V. Adhesive proteins of the malaria parasite. *Current Opinion in Microbiology* (in press)
138. Cowman AF. The molecular basis of resistance to the sulfones sulfonamides and the dihydrofolate reductase inhibitors. In: Sherman IW, ed. *Malaria: parasite biology pathogenesis and protection*. Washington: ASM Press (in press)
139. Foote SJ, Speed TP and Handman E. What can bioinformatics do for parasitology research? *Parasitol Today* 14: 346–347, 1998

Autoimmunity and Transplantation Division

Primary

140. Allison JA, Stephens LA, Kay TW, Kurts C, Heath WR, Miller JFAP and Krummel MF. The threshold for autoimmune T-cell killing is influenced by B7-1. *Eur J Immunol* 28: 949–960, 1998
141. Augstein P, Elefanti AG, Allison J and Harrison LC. Apoptosis and β -cell destruction in pancreatic islets of NOD mice with spontaneous and cyclophosphamide accelerated diabetes. *Diabetologia* (in press)
142. Augstein P, Stephens LA, Allison J, Elefanti AG, Ekberg M, Kay TWH and Harrison LC. β -cell apoptosis in an accelerated model of autoimmune diabetes. *Mol Med* (in press)
143. Boyle JS, Brady JL, Koniaras C and Lew AM. Inhibitory effect of lipopolysaccharide on immune response after DNA immunization is route dependent. *DNA Cell Biol* 17: 343–348, 1998
144. Boyle JS, Brady JL and Lew AM. Enhanced responses to a DNA vaccine encoding a fusion antigen that is directed to sites of immune induction. *Nature* 392: 408–411, 1998
145. Boyle JS, Koniaras C and Lew AM. Influence of cellular location of expressed antigen on the efficacy of DNA vaccination: cytotoxic T lymphocyte and antibody responses are suboptimal when antigen is cytoplasmic after intramuscular DNA immunization. *Int Immunol* 9: 1897–1906, 1997
146. Boyle JS, Silva A, Brady A, Brady JL and Lew AM. DNA immunization: induction of higher avidity antibody and effect of route T-cell cytotoxicity. *Proc Natl Acad Sci USA* 94: 14626–14631, 1997
147. Colman PG, McNair P, Margetts H, Schmidli R, Werther GA, Alford FP, Ward GM, Tait BD, Honeyman MC and Harrison LC. The Melbourne Pre-Diabetes Study: prediction of type 1 diabetes mellitus using antibody and metabolic testing. *Med J Aust* 169: 81–84, 1998
148. Couper JJ, Harrison LC, Aldis JJE, Colman PG and Honeyman MC. IgG subclass antibodies to glutamic acid decarboxylase and risk for progression to clinical insulin-dependent diabetes. *Hum Immunol* (in press)
149. Daniel S, Brusica V, Caillat-Zucman S, Petrovsky N, Harrison LC, Riganelli D, Sinigaglia F, Gallazzi F, Hammer J and Van Endert PM. Relationship between peptide selectivities of human transporters associated with antigen processing and HLA class I molecules. *J Immunol* 161: 617–624, 1998
150. Eisenbarth GS, Gianani R, Yu L, Pietropaolo M, Verge CF, Chase HP, Redondo MJ, Colman P, Harrison LC and Jackson R. Dual-parameter model for prediction of type 1 diabetes mellitus. *Proc Assoc Am Physicians* 110: 126–135, 1998
151. Foote SJ, Burt RA, Baldwin TM, Presente A, Roberts AW, Loral YL, Lew AM and Marshall VM. Mouse loci for malaria-induced mortality and the control of parasitaemia. *Nat Genet* 17: 380–381, 1997
152. Fox A, Koulmanda M, Mandel TE, van Rooijen N and Harrison LC. Evidence that macrophages are required for T-cell infiltration and rejection of fetal pig pancreas xenografts in NOD mice. *Transplantation* (in press)
153. Honeyman MC, Brusica V and Harrison LC. Strategies for identifying and predicting islet autoantigen T-cell epitopes in insulin-dependent diabetes mellitus. *Ann Med* 29: 401–404, 1997
154. Honeyman MC, Stone NL and Harrison LC. T-cell epitopes in type 1 diabetes autoantigen tyrosine phosphatase IA-2: potential for mimicry with rotavirus and other environmental agents. *Mol Med* 4: 231–239, 1998
155. Kay TW, Chaplin HL, Parker JL, Stephens LA and Thomas HE. CD4⁺ and CD8⁺ T lymphocytes: clarification of their pathogenic roles in diabetes in the NOD mouse. *Res Immunol* 148: 320–327, 1997
156. Koniaras C, Heath WR and Lew AM. T-cell unresponsiveness *in vitro* can be due to activation *in vivo*. *Int Immunol* 10: 365–369, 1998
157. Koulmanda M, Kovarik J and Mandel TE. Cyclophosphamide, but not CTLA4Ig prolongs survival of fetal pig islet grafts in anti-T cell monoclonal antibody treated NOD mice. *Xenotransplantation* (in press)
158. Kovarik J, Koulmanda M and Mandel TE. The role of cytokines during rejection of foetal pig and foetal mouse pancreas grafts in NOD mice. *Transpl Immunol* 5: 307–314, 1998
159. Martin RM, Brady JL and Lew AM. The need for IgG2c specific antiserum when isotyping antibodies from C57BL/6 and NOD mice. *J Immunol Methods* 212: 187–192, 1998
160. Morahan G, Huang DCS, Yu WP, Cui L, DeAizpurua H and Pallen CJ. Localization of the genes encoding the type 1 diabetes autoantigens, protein-tyrosine phosphatases IA2 and IAR. *Mamm Genome* 9: 593–594, 1998
161. Myers MA, Feeney SJ, Mandel TE, Koulmanda M, Bone M, Barley J, Rowley MJ and Mackay IR. Antibodies to ICA512 in rodent models of IDDM. *J Autoimmun* 11: 265–272, 1998
162. Petrovsky N, McNair P and Harrison LC. Diurnal rhythms of pro-inflammatory cytokines: regulation by plasma cortisol and therapeutic implications. *Cytokine* 10: 307–312, 1998
163. Ramakrishna V, Negri DRM, Brusica V, Fontanelli R, Canevari S, Bolis G, Castelli C and Parmiani G. Generation and phenotypic characterization of new human ovarian cancer cell lines with the identification of antigens potentially recognizable by HLA-restricted cytotoxic T cells. *Int J Cancer* 73: 143–150, 1997
164. Rentsch JL, Liedel JL, Bayley NB, Buchanan MR, Goldblatt JC, Warren RJ and Kay TW. Giant cell arteritis (GCA) presenting with severe aortic regurgitation and a normal ESR. *Aust N Z J Med* 28: 70–71, 1998
165. Rentsch JL, Martin EM, Harrison LC and Wicks IP. Prolonged response of multicentric reticulohistiocytosis to low dose methotrexate. *J Rheumatol* 25: 1012–1015, 1998
166. Schmidli RS, Colman PG, Cui L, Yu WP, Kewming K, Jankulovski C, Harrison LC, Pallen CJ and DeAizpurua HJ. Antibodies to the novel protein tyrosine phosphatase IAR predict development of insulin-dependent diabetes (IDDM) in first degree relatives at risk for IDDM. *Autoimmunity* (in press)
167. Stambe C and Wicks I. TNF α and response of treatment-resistant adult-onset Still's disease to thalidomide. *Lancet* (in press)
168. Takahashi K, Honeyman MC and Harrison LC. Impaired yield, phenotype and function of monocyte-derived dendritic cells in humans at risk for insulin-dependent diabetes. *J Immunol* (in press)
169. Thomas HE, Parker JL, Schreiber RD and Kay TWH. Transgenic non-obese diabetic mice expressing dominant negative IFN- γ receptors: IFN- γ action on pancreatic beta cells causes class I MHC upregulation but not diabetes. *J Clin Invest* (in press)

Reviews and Books

170. Boyle JS, Agius CT, Lew AM and Bar IG. DNA vaccines: will they deliver? *Australas Biotechnol* 8: 153–159, 1998
171. Brusica V, Rudy G and Harrison LC. MHCPEP, a database of MHC-binding peptides: update 1997. *Nucleic Acids Res* 26: 368–371, 1998
172. Harrison LC. Diabetes back to the future. In: Phillips P, ed. *Diabetes and you: an owner's manual* (in press)
173. Harrison LC, Kay TWH, Colman PG and Honeyman MC. Type 1 diabetes – from pathogenesis to prevention. In: *Diabetes in the new millennium* (in press)
174. Honeyman MC and Harrison LC. Immunity: humoral and cellular. In: *Encyclopedia of life sciences* (in press)
175. Koulmanda M and Auchincloss H. Literature update 1998, part 1. *Xenotransplantation* (in press)

176. Petrovsky N and Harrison LC. The chronobiology of human cytokine production. *Intern Rev Immunol* 16: 635–649, 1998
177. Martin RM and Lew AM. Is IgG2a a good Th1 marker in mice. *Immunol Today* 19: 49, 1998
178. Wicks I. The pathogenesis of synovitis. *APLAR J Rheum* 1: 245–247, 1998

Development and Neurobiology Group

Primary

179. Arber S, Barbayannis FA, Hanser H, Schneider C, Stanyon CA, Bernard O and Caroni P. Regulation of actin dynamics through phosphorylation of cofilin by LIM-kinase. *Nature* 393: 805–809, 1998
180. Barrett GL, Georgiou A, Reid K, Bartlett PF and Leung D. Rescue of dorsal root sensory neurons by nerve growth factor and neutrophin-3, but not brain derived neurotrophic factor or neutrophin-4, is dependent on the level of the p75 neutrophin receptor. *Neuroscience* 85: 1321–1328, 1998
181. Bartlett PF, Brooker GJ, Faux CH, Dutton R, Murphy M and Kilpatrick TJ. Regulation of neural stem cell differentiation in the forebrain. *Immunol Cell Biol* (in press)
182. Bernard O, Bernard R, Beart P and Offend D. The function of survival and death genes in the nervous system. *J Neurochem* 70: 5286, 1998
183. Bernard R, Dieni S, Rees S and Bernard O. Physiological and induced neuronal death are not affected in NSE-*bax* transgenic mice. *J Neurosci Res* 52: 247–259, 1998
184. Biben C, Hatzistavrou T and Harvey RP. Expression of *NKx-2* class homeobox gene *Nkx2-6* in foregut endoderm and heart. *Mech Dev* 73: 125–127, 1998
185. Biben C, Stanley E, Fabri L, Kotecha S, Rhinn M, Drinkwater C, Lah M, Wang CC, Nash A, Hilton DJ, Ang SL, Mohun T and Harvey RP. Murine cerberus homologue *mCer-1*: a candidate anterior patterning molecule. *Dev Biol* 194: 135–151, 1998
186. Brickman YG, Ford MD, Gallagher JT, Nurcombe V, Bartlett PF and Turnbull JE. Structural modification of fibroblast growth factor-binding heparan sulfate at a determinative stage of neural development. *J Biol Chem* 273: 4350–4359, 1998
187. Brickman YG, Nurcombe V, Ford MD, Gallagher JT, Bartlett PF and Turnbull JE. Structural comparison of fibroblast growth factor-specific heparan sulfates derived from a growing or differentiating neuroepithelial cell line. *Glycobiology* 8: 463–471, 1998
188. Cheema SS, Arumugam D, Murray SS and Bartlett PF. Leukemia inhibitory factor maintains choline acetyltransferase expression *in vivo*. *Neuroreport* 9: 363–366, 1998
189. Dottori M, Hartley, Galea M, Paxinos G, Kilpatrick TJ, Bartlett PF, Murphy M, Köntgen F, Boyd AW. EphA4 receptor tyrosine kinase is required for the development of the corticospinal tract. *Proc Natl Acad Sci USA* (in press)
190. Ford M, Cauchi J, Greferath U, Bertram J. Expression of fibroblast growth factors and their receptors in the rat glomeruli. *Kidney Int* (in press)
191. Harvey RP. Cardiac looping: an uneasy deal with laterality. *Semin Cell Dev Biol* 9: 101–108, 1998
192. Harvey AR, Symons NA, Pollett MA, Brooker GJ and Bartlett PF. Fate of adult neural precursors grafted to adult cortex monitored with a Y-chromosome marker. *Neuroreport* 8: 3939–3943, 1997
193. Hearn CJ, Murphy M and Newgreen D. GDNF and ET-3 differentially modulate the numbers of avian enteric neural crest cells and enteric neurons *in vitro*. *Dev Biol* 197: 93–105, 1998
194. Ikebe C, Ohashi K, Fujimori T, Bernard O, Noda T, Robertson EJ and Mizuno K. Mouse LIM-kinase 2 gene: cDNA cloning, genomic organization, and tissue-specific expression of two alternatively initiated transcripts. *Genomics* 46: 504–508, 1997
195. Koblar SA, Turnley AM, Classon BJ, Reid KL, Ware CB, Cheema SS, Murphy M and Bartlett PF. Neural precursor differentiation into astrocytes requires signaling through the LIF receptor. *Proc Natl Acad Sci USA* 95: 3178–3181, 1998
196. Kurek JB, Bower JJ, Romanella M, Köntgen F, Murphy M and Austin L. The role of leukemia inhibitory factor in skeletal muscle regeneration. *Muscle Nerve* 20: 815–822, 1997
197. Marzella PL, Clark GM, Shepherd RK, Bartlett PF and Kilpatrick TJ. Synergy between TGF- β 3 and NT-3 to promote the survival of spiral ganglia neurones *in vitro*. *Neurosci Lett* 240: 77–80, 1998
198. Offen D, Beart PM, Cheung NS, Pascoe CJ, Hochman A, Gorodin S, Melamed E, Bernard R and Bernard O. Transgenic mice expressing human Bcl-2 in their neurons are resistant to 6-hydroxydopamine and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity. *Proc Natl Acad Sci USA* 95: 5789–5794, 1998
199. Puche AC, Bartlett PF and Key B. Substrate-bound carbohydrates stimulate signal transduction and neurite outgrowth in an olfactory neuron cell line. *Neuroreport* 8: 3183–3188, 1998
200. Ranganayakulu G, Elliot DA, Harvey RP and Olson EN. Divergent roles for *Nk-2* class homeobox genes in cardiogenesis in flies and mice. *Development* (in press)
201. Robb L, Mifsud L, Hartley L, Biben C and Harvey RP. Epicardin: a basic helix–loop–helix transcription factor gene expressed in epicardium, branchial arch myoblasts and mesenchyme of lung, gut, kidney and gonads. *Dev Dyn* (in press)
202. Stanley E, Gilbert DG, Jenkins NA, Copeland NG and Harvey RP. Murine *cerberus* homologue *mCer-1* maps to chromosome 4. *Genomics* 49: 337–338, 1998
203. Turnley AM and Bartlett PF. MAG and MOG enhance neurite outgrowth of embryonic mouse spinal cord neurons. *Neuroreport* 9: 1987–1990, 1998
204. Uren AG, Coulson EJ and Vaux DL. Conservation of baculovirus inhibitor of apoptosis repeat proteins (BIRPs) in viruses, nematodes, vertebrates and yeasts. *Trends Biochem Sci* 23: 159–162, 1998
205. Walz A, McFarlane S, Brickman YG, Nurcombe V, Bartlett PF and Holt CE. Essential role of heparan sulfates in axon navigation and targeting in the developing visual system. *Development* 124: 2421–2430, 1997

Reviews and Books

206. Biben C, Palmer S, Elliott DA and Harvey RP. Homeobox genes and heart development. *Cold Spring Harb Symp Quant Biol* 62: 395–403, 1997
207. Epa WR, Barrett GL and Bartlett PF. Oglionucleotides as inhibitors of protein synthesis. *Methods Mol Biol* (in press)
208. Harvey RP. *Nkx2.5* controls myogenesis and morphogenesis in the developing mammalian heart. In: Harvey RP, Olson EN, Schultz RA and Altman JS, eds. *Genetic control of heart development: workshop III*. Strasbourg: Human Frontier Science Program; 55–62, 1997
209. Harvey RP, Olson EN, Schultz RA and Altman J eds. *Genetic control of heart development: workshop III*. Strasbourg: Human Frontiers Science Program, 1997
210. Newgreen DF and Murphy M. Neural crest cell outgrowth and the analysis of cell migration. In: *Developmental Biology Protocols* (in press)
211. Stanyon CA and Bernard O. Molecules in focus: LIM kinase. In: *Int J Biochem Cell Biol* (in press)

Primary

212. Allison JA, Stephens LA, Kay TW, Kurts C, Heath WR, Miller JFAP and Krummel MF. The threshold for autoimmune T cell killing is influenced by B7-1. *Eur J Immunol* 28: 949–960, 1998

213. Augstein P, Elefanty AG, Allison J and Harrison LC. Apoptosis and β -cell destruction in pancreatic islets of NOD mice with spontaneous and cyclophosphamide-accelerated diabetes. *Diabetologia* (in press)

214. Augstein P, Stephens LA, Allison J, Elefanty AG, Ekberg M, Kay TWH and Harrison LC. β -cell apoptosis in an accelerated model of autoimmune diabetes. *Mol Med* (in press)

215. Barnden MJ, Allison J, Heath WR and Carbone FR. Defective TCR expression in transgenic mice constructed using cDNA-based alpha- and beta-chain genes under the control of heterologous regulatory elements. *Immunol Cell Biol* 76: 34–40, 1998

216. Chataway TK, Whittle AM, Lewis MD, Bindloss CA, Moritz RL, Simpson RJ, Hopwood JJ and Meikle PJ. Development of a two-dimensional gel electrophoresis database of human lysosomal proteins. *Electrophoresis* 19: 834–836, 1998

217. Chen YC, Reid GE, Simpson RJ and Truscott RW. Molecular evidence for the involvement of alpha crystallin in the colouration /crosslinking of crystallin in age-related nuclear cataract. *Exp Eye Res* 65: 835–840, 1997

218. Foote SJ, Burt RA, Baldwin TM, Presente A, Roberts AW, Lustral YL, Lew AM and Marshall VM. Mouse loci for malaria-induced mortality and the control of parasitaemia. *Nat Genet* 17: 380–381, 1997

219. Ford CM, Paltridge NG, Rathjen JP, Moritz RL, Simpson RJ and Symons RH. Rapid and informative assays for Yd2, the barley yellow dwarf virus resistance gene, based on the nucleotide sequence of a closely linked gene. *Mol Breeding* 4: 23–31, 1998

220. Grover PK, Moritz RL, Simpson RJ and Ryall RL. Inhibition of growth and aggregation of calcium oxalate crystals *in vitro* – a comparison of four human proteins. *Eur J Biochem* 253: 637–644, 1998

221. Hammacher A, Reid GE, Moritz RL and Simpson RJ. Identification and characterization of recombinant murine interleukin-6 with a C-terminal pentapeptide extension using capillary reversed phase HPLC-MS and Edman degradation. *Biomed Chromatogr* 11: 337–342, 1997

222. Hammacher A, Richardson RT, Layton MJ, Smith DK, Argus L, Hilton DJ, Nicola NA, Wijdenes J and Simpson RJ. The immunoglobulin-like module of gp130 is required for signalling by interleukin-6 but not leukemia inhibitory factor. *J Biol Chem* (in press)

223. Heath JK, White SJ, Johnstone CN, Catimel B, Simpson RJ, Moritz RL, Tu GF, Ji H, Whitehead RH, Groenen LC, Scott AM, Ritter G, Cohen L, Welt S, Old LJ, Nice EC and Burgess AW. The human A33 antigen is a transmembrane glycoprotein and a novel member of the immunoglobulin superfamily. *Proc Natl Acad Sci USA* 94: 469–474, 1997

224. Holmes ML, Scopes RK, Moritz RL, Simpson RJ, Englert C, Pfeifer F and Dyal-Smith ML. Purification and analysis of an extremely halophilic β -galactosidase from *haloferax alicantei*. *Biochim Biophys Acta* 1337: 276–286, 1997

225. Kurts K, Carbone FR, Barnden M, Blanas E, Allison J, Heath WR and Miller JFAP. CD4⁺ T cell help impairs CD8⁺ T cell deletion induced by cross-presentation of self-antigens and favors autoimmunity. *J Exp Med* 186: 2057–2062, 1997

226. Matthews JM, Hammacher A, Howlett GJ and Simpson RJ. Physicochemical characterisation of an antagonistic human interleukin-6 dimer. *Biochemistry* 37: 10671–10680, 1998

227. Morahan G, Huang DCS, Yu WP, Cui L, DeAizpurua H and Pallen CJ. Localization of the genes encoding the type I diabetes

autoantigens, protein-tyrosine phosphatases IA2 and IAR. *Mamm Genome* 9: 593–594, 1998

228. Moritz RL, Ritter G, Catimel B, Cohen LS, Welt S, Old LJ, Burgess AW, Nice EC and Simpson RJ. Micro-sequencing strategies for the human A33 antigen, a novel surface glycoprotein of human gastrointestinal epithelium. *J Chromatogr A* 798: 91–101, 1998

229. Rasmussen RK, Ji H, Eddes JS, Moritz RL, Reid GE, Simpson RJ and Dorow DS. Two-dimensional electrophoretic analysis of mixed lineage kinase 2 N-Terminal domain binding proteins. *Electrophoresis* 19: 809–817, 1998

230. Rasmussen RK, Ji H, Eddes JS, Zugaro LM, Reid GE, Simpson RJ and Dorow DS. Two-dimensional gel database of human breast carcinoma cell expressed proteins – an update. *Electrophoresis* 19: 818–825, 1998

231. Reid GE, Rasmussen RK, Dorow DS and Simpson RJ. Capillary column chromatography improves sample preparation for mass spectrometric analysis – complete characterization of human alpha-enolase from two-dimensional gels following *in situ* proteolytic digestion. *Electrophoresis* 19: 946–955, 1998

232. Reid GE, Simpson RJ and O’Hair RAJ. Mass spectrometric and an initio study of the pathways for dehydration of simple glycine and cysteine containing peptide [M+H]⁺ ions. *J Am Soc Mass Spectrom* (in press)

233. Ritter G, Cohen LS, Nice EC, Catimel B, Burgess AW, Moritz RL, Ji H, Heath JK, White SJ, Welt S, Old LJ and Simpson RJ. Characterization of posttranslational modifications of human A33 antigen, a novel palmitoylated surface glycoprotein of human gastrointestinal epithelium. *Biochem Biophys Res Commun* 236: 682–686, 1997

234. Tavner FJ, Simpson R, Tashiro S, Favier D, Jenkins NA, Gilbert DJ, Copland NG, Keough RA, Ishii S and Gonda TJ. Molecular cloning reveals that the p160 myb-binding protein is a novel, predominantly nucleolar protein which may play a role in transactivation by myb. *Mol Cell Biol* 18: 989–1002, 1998

235. Zhang JG, Zhang Y, Owczarek CM, Ward LD, Moritz RL, Simpson RJ, Yasukawa K and Nicola NA. Identification and characterization of two distinct truncated forms of gp130 and a soluble form of leukemia inhibitory factor receptor alpha-chain in normal human urine and plasma. *J Biol Chem* 273: 10798–10805, 1998

236. Zugaro LM, Reid GE, Ji H, Eddes JS, Murphy AC, Burgess AW and Simpson RJ. Characterization of rat brain stathmin isoforms by two-dimensional gel electrophoresis matrix assisted laser desorption/ ionization and electrospray ionization ion trap mass spectrometry. *Electrophoresis* 19: 867–876, 1998

Reviews and Books

237. Allison J, Seino K and Yagita H. Can expression of CD95 (Fas/APO-1) ligand on grafts or tumor cells prevent their rejection? *Springer Semin Immunopathol* 19: 311–322, 1998

238. Baird PN. Response to Pritchard-Jones and Renshaw. *Exp Hematol* 25: 1312, 1997

239. Dosremedios C and Simpson R. Bright sparks in Australian 2-DE: Report on the fourth annual conference of the Australian Electrophoresis Society. *Electrophoresis* 19: 807–808, 1998

240. Foote SJ, Speed TP and Handman E. What can bioinformatics do for parasitology research? *Parasitol Today* 14: 346–374, 1998

241. Miller JFAP, Kurts C, Allison JA, Kosaka H, Carbone FR and Heath WR. Induction of peripheral CD8⁺ T-cell tolerance by cross-presentation of self antigens. *Immunol Rev* (in press)

242. Morahan G. Genetic analysis of type 1 diabetes. *Today’s Life Sci* 10: 32–35, 1998

243. Simpson RJ and Reid GE. Sequence analysis of gel-resolved proteins. In: Hames BD, ed. *Gel electrophoresis of proteins: a practical approach*. New York: Oxford University Press (in press)

244. Strasser A, Newton K, Huang DCS, O’Connor L, O’Reilly LA, Puthalakath H, Bath ML, Cullen L, Stanley ML, Tarlinton DM, Allison J, Smith KGC, Vaux DL, Adams JM, Cory S and Harris

AW. The molecular control of lymphocyte apoptosis. In: *Proceedings of the 5th Euro-conference on apoptosis*. Bingen, Germany: European School of Haematology; 7pp, 1997.

Advanced Technologies

Primary

245. Diener K, Tessier P, Fraser J, Köntgen F, McColl SR. Induction of acute inflammation *in vivo* by staphylococcal superantigens I: Leukocyte recruitment occurs independently of T lymphocytes and major histocompatibility complex Class II molecules. *Lab Invest* 78: 647–656, 1998
246. Dottori M, Hartley, Galea M, Paxinos G, Kilpatrick TJ, Bartlett PF, Murphy M, Köntgen F, Boyd AW. EphA4 receptor tyrosine kinase is required for the development of the corticospinal tract. *Proc Natl Acad Sci USA* (in press)
247. Korner H, Cook M, Riminton DS, Lemckert FA, Hoek RM, Ledermann B, Köntgen F, Fazekas de St Groth B, Sedgwick JD. Distinct roles for lymphotoxin- α and tumor necrosis factor in organogenesis and spatial organization of lymphoid tissue. *Eur J Immunol* 27: 2600–2609, 1997
248. Kurek JB, Bower JJ, Romanella M, Koentgen F, Murphy M, Austin L. The role of leukemia inhibitory factor in skeletal muscle regeneration. *Muscle Nerve*. 20: 815–22, 1997
249. Li S, Kurts C, Köntgen F, Holdsworth SR and Tipping PC. MHC class II expression by intrinsic renal cells is required for crescentic glomerulonephritis. *J Exp Med* 188: 597–602, 1998
250. Robb L, Li R, Hartley L, Nandurkar HH, Koentgen F, Begley CG. Infertility in female mice lacking the receptor for interleukin 11 is due to a defective uterine response to implantation. *Nat Med* 4: 303–308, 1998

Reviews and Books

251. Barlow JW, Ewen KR. High-throughput genotyping. *Today's Life Sci*, 10: 16–21, 1998

Patents

• A method for enhancing neuron survival and reagents useful for same

Inventor:

Graeme Barrett

Australia 689145 (granted 1998)

• Leukaemia Inhibitory Factor

Inventors:

David Paul Gearing

Nicholas Martin Gough

Douglas James Hilton

Julie Ann King

Donald Metcalf

Edouard Collins Nice

Nicos Anthony Nicola

Richard John Simpson

Tracy Ann Willson

Japan 2682858, 2721123 (granted 1998)

Korea 121324, 121322 (granted 1997)

United States 5750654 (granted 1998)

• In vitro propagation of embryonic stem cells

Inventors:

Nicholas Martin Gough

Douglas James Hilton

Robert Lindsay Williams

Japan 2740320 (granted 1998)

• Improvements in granulocyte-macrophage colony-stimulating factor receptor and derivatives thereof

Inventors:

Nicos Anthony Nicola

Donald Metcalf

Nicholas Martin Gough

David Paul Gearing

Julie Ann King

Europe 0486572 (granted 1998)

United States 5726036 (granted 1998)

• Monoclonal Antibody

Inventors:

Nicos Anthony Nicola

Andrew Wallace Boyd

Kaye Wycherley

Judith Eleanor Layton

Donald Metcalf

United States 5747032 (granted 1998)

• Novel Fusion Protein

Inventor:

Donald Bruce Smith

United States 5654176 (granted 1997)